• Overview
  Quotes Prices Key Stats News Press Releases Sentiment
• Charts
  Chart Technicals
• Company
  Splits Dividends Recommendations Price Target Insider Trades Holders Peers Filings Notes due Fail to deliver ESG Score Executive Compensation Profile
• Earnings
  Price Reaction Earnings Estimates Trends Call Transcripts
• Financials
  Fundamentals DCF Beta
• Options
  Option Chain Option Strategies Put/Call Ratios
• Analysis
  Up/Down Intra-day Events Performance Recovery Returns Price Distribution Unusual Volume Best Days Data Correlations Seasonality Volatility Trader Stats

Summary

News

05/10 08:00 EST - businesswire.com
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in May: 2024 RBCCM Global Healthcare Conference (New York, NY): Presentation on Tuesday, May 14, 2024, at 8:30 a.m. ET. BofA Securities 2024 Health Care Conference (Las Vegas, NV): Present.

05/08 14:27 EST - seekingalpha.com
Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Louisa Stone – Manager of Investor Relations Steve Mahoney – President and CEO Tom Ciulla – Chief Medical Officer Conference Call Participants Laura Chico – Wedbush Alex Thompson – Stifel Michael Yee – Jefferies Gavin Clark-Gartner – Evercore Rami Katkhuda – LifeSci Capital Gregory Renza – RBC Julian Harrison – BTIG Trevor Allred – Oppenheimer Operator Welcome to the Viridian Therapeutics First Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.

05/08 09:25 EST - zacks.com
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.61 per share a year ago.

05/08 07:00 EST - businesswire.com
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ending March 31, 2024. “It has been a remarkable first quarter of execution as we made progress across our TED and neonatal Fc receptor (FcRn) inhibitor programs,” said Steve Mahoney, Viridian President and Ch.

05/07 19:33 EST - globenewswire.com
Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village
PALO ALTO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Multifamily owner-operator and investment manager Pacific Urban Investors (“Pacific”) has acquired Viridian, a 420-unit apartment community in Greenwood Village, CO. Viridian (the “Property”) is located in the Denver Tech Center, adjacent to thousands of high paying technology, financial services, telecommunications, and aerospace jobs. The acquisition marks Pacific's fourth investment in the Denver market with the firm's regional portfolio now totaling 884 units.

05/03 08:00 EST - businesswire.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 551,000 shares of the company's common stock to.

03/29 09:00 EST - prnewswire.com
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
PHILADELPHIA , March 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Viridian Therapeutics, Inc. (NASDAQ: VRDN) ("Viridian") on behalf of the company's shareholders. The investigation seeks to determine whether Viridian and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's shareholders in connection with recent corporate actions.

03/19 18:51 EST - investorplace.com
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
Inflation has been the scourge of American households since the Covid-19 disruption. But investors can attempt to beat rising prices with stocks under $20.

02/28 10:56 EST - zacks.com
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to a 97.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

02/27 16:01 EST - businesswire.com
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023. “Throughout 2023, we delivered important clinical results across our TED portfolio, marking significant progress for the company,” said Steve Mahoney, Viridian President.

02/16 08:00 EST - businesswire.com
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer. “I am very pleased to welcome Jennifer to Viridian to lead our legal team and join Viridian's executive team ahead of an exciting set of milestones this year across our t.

02/06 16:01 EST - businesswire.com
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to an employee to purchase up to 30,000 shares of the company's common stock.

01/27 13:09 EST - 24/7 Wall Street
Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More
Overall, the number of notable insider purchases may have dwindled with the earnings-reporting season in full swing, but there were still some huge, headline-making buys in the past week or so.

01/17 22:00 EST - businesswire.com
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering with gross proceeds of approximately $150.0 million. Viridian is selling a total of 7,142,858 shares of common stock at a public offering price of $21.00 per share. In addition, Viridian has granted the underwriters a 30-day option.

01/17 16:01 EST - businesswire.com
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and Series B preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian intends to grant the underwriters a 30-day.

01/08 08:00 EST - businesswire.com
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that President and Chief Executive Officer, Steve Mahoney, will discuss the company's progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. As part of Viridian's presentation at the J.P. Morgan Healthcare Conference, Mr. Mahoney will provide.

12/29 11:23 EST - seekingalpha.com
Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023
Shares of Viridian Therapeutics underperformed this year. Negative biotech sentiment was partly to blame, as well as Tepezza's Y/Y net sales declines, and some internal turmoil with two CEO changes. These events overshadowed many positive developments in the company's TED pipeline, and more recently, the pipeline expansion with two preclinical anti-FcRn candidates.

12/26 17:21 EST - CNBC Television
Wedbush's Laura Chico talks biotech investing in 2024
Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.